menu
    • menu

    Company profile for Swedish Orphan Biovitrum AB

    NEW Drugs in Dev: 26
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise t...
    Sobi is an international biopharmaceutical company focused on rare diseases. We are dedicated to providing access to innovative treatments that transform life for people with rare diseases. We focus on two therapeutic areas – Haematology and Immunology – and also have a portfolio of Specialty Care products. Within Haematology, we have become a leading company in haemophilia, where we seek to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care. Our Immunology portfolio, with three strongly growing products that each meet high unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Swedish Orphan Biovitrum ABSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Tomtebodavägen 23A Solna
    Telephone
    Telephone
    +46(0)8 697 20 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sobi.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sobi/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arab Health

    Arab Health

    Not Confirmed

    envelop Contact Supplier

    Arab Health

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sobi Gets EU Approval For Aspaveli In C3G And Primary IC-MPGN
    Sobi Gets EU Approval For Aspaveli In C3G And Primary IC-MPGN

    16 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobi-receives-european-commission-approval-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn-302663349.html

    PR NEWSWIRE
    16 Jan 2026
    Share Share
    Sobi Exceeds Previous Outlook With 2025 Revenue And EBITA Margin
    Sobi Exceeds Previous Outlook With 2025 Revenue And EBITA Margin

    15 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobis-2025-annual-revenue-and-adjusted-ebita-margin-exceed-previous-outlook-302662353.html

    PR NEWSWIRE
    15 Jan 2026
    Share Share
    Invitation to Sobi's Q4 & FY 2025 Report
    Invitation to Sobi's Q4 & FY 2025 Report

    14 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invitation-sobis-q4-and-fy-2025-report-302661008.html

    PR NEWSWIRE
    14 Jan 2026
    Share Share
    Sobi Advances Gamifant In Interferon-Gamma-Driven Sepsis
    Sobi Advances Gamifant In Interferon-Gamma-Driven Sepsis

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sobi-to-advance-gamifant-emapalumab-in-interferon-gamma-driven-sepsis-ids-based-on-embrace-topline-data-302655472.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Sobi To Host Capital Markets Day On February 18, 2026
    Sobi To Host Capital Markets Day On February 18, 2026

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/save-the-date-sobi-to-host-a-capital-markets-day-on-18-february-2026-302645751.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Sobi to buy US Biotech Arthrosi for up to $1.5 B
    Sobi to buy US Biotech Arthrosi for up to $1.5 B

    13 Dec 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/swedens-sobi-buy-arthrosi-therapeutics-15-billion-2025-12-13/

    REUTERS
    13 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search